Intraosseous basivertebral nerve ablation: A 5-year pooled analysis from three prospective clinical trials
In this 5-year aggregate analysis, BVNA significantly improved pain and function scores compared to baseline. Similarly, there were significant reductions in opioid consumption and spinal injections post BVNA. Data demonstrate a strong safety profile with no serious device or device-related events and low healthcare utilization rate for the same index pain source through a mean of 5.6 years. Results demonstrate that intraosseous BVNA treatment for patients with vertebrogenic pain is safe, effective, and durable through five years.
Authors
- Jad G. Khalil (ORCID: https://orcid.org/0000-0002-2489-1907)
- Eeric Truumees (ORCID: https://orcid.org/0000-0002-3319-3270)
- Kevin Macadaeg
- Jeffrey S. Fischgrund (ORCID: https://orcid.org/0000-0003-4658-5991)
- D.T. Nguyen
- Dylan Lukes
- Gregory Moore
Institutions
- Pacific University Oregon (US)
- Oakland University (US)
- Oklahoma Christian University (US)
- Beaumont Hospital, Royal Oak (US)
- Beaumont Hospital (US)
- Ascension Via Christi (US)
- Indiana Spine Group (US)
- Data Management (Italy) (IT)
- Indiana University (US)
Publication Details
- Journal
- Interventional Pain Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.inpm.2024.100529
- Citations
- 3
- Primary Topic
- Spine and Intervertebral Disc Pathology
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- Boston Scientific Corporation
- Relievant Medsystems